To assess the superiority of fesoterodine 8 mg vs 4 mg for improvement in urgency urinary incontinence ( UUI ) episodes and other diary variables , diary-dry rate ( proportion of patients with > 0 UUI episodes on baseline diary and 0 UUI episodes on post-baseline diary ) , and improvements in measures of symptom bother , health-related quality of life ( HRQL ) , and other patient-reported outcomes ( PROs ) .